In BC, the expression of NKG2A is associated with a better response to anti-PD-L1 therapy in cancers with higher levels of CD8A, PDCD1, or PD-L1, suggesting that NKG2A could be a predictive biomarker [9]. Here, PDCD1 is linked to cancer.